Urinary excretion of homocysteine-thiolactone in humans

Clinical Chemistry

Volumn 51, Issue 2, 2005, Pages 408-415

  Chwatko, Grazyna ^a,c   Jakubowski, Hieronim ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HOMOCYSTEINE THIOLACTONE;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID URINE LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE CLEARANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISCHEMIC HEART DISEASE; PROTON TRANSPORT; URINARY EXCRETION;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORESCENCE; HOMOCYSTEINE; HUMANS; MIDDLE AGED; PLASMA;

EID: 12944309749     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.042531     Document Type: Article

References (39)

1. Clarke R, Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis JAMA 2002;288:2015-22.
2. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000;102:1227-32.
3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Altzheimer's disease. N Engl J Med 2002;346: 476-83.
4. Lawrence de Konig AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36:431-41.
5. Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci 2004;61:470-87.
6. Jakubowski H. Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med 2003;41:1462-6.
7. Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr 2001:131(Suppl):2983-7.
8. Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Analyt Biochem 2002;308:112-9.
9. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-41.
10. Langmeier M, Folbergrova J, Haugvicova R, Pokorny J, Mares PT. Neuronal cell death in hippocampus induced by homocysteic acid in immature rats. Epilepsia 2003;44:299-304.
11. Greene NE, Dunlevy LE, Copp AJ. Homocysteine is embryotoxic but does not cause neural tube defects in mouse embryos. Anat Embryol (Berl) 2003;206:185-91.
12. Van Aertes LA, Klaasboer HH, Postma NS, Pertijs JC, Peereboom JH, Eskes TK, et al. Stereospecific in vitro embryotoxicity of L-homocysteine in pre- and post-implantation rodent embryos. Toxicol In Vitro 1993;6:743-9.
13. Rosenquist, TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: effect of folic acid. Proc Natl Acad Sci U S A 1996;93:15227-32.
14. Hansen DK, Grafton F, Melnyk S, James JS. Lack of embryotoxicity of homocysteine thiolactone in mouse embryos in vitro. Reprod Toxicol 2001;15:239-44.
15. Mercie P, Garnier O, Lascoste L, Renard M, Closse C, Durrieu F. et al. Homocysteine thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis 2000;5:403-11.
16. Huang RF, Huang SM, Lin BS, Wei JS, Liu TZ. Homocysteine thiolactone induces apoptotic DNA damage mediated by increased intracellular hydrogen peroxide and caspase 3 activation in HL-60 cells. Life Sci 2001;68:2799-811.
17. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling and glutathione has a protective effect. J Mol Endocrinol 2001;27:85-91.
18. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem 1997;272:1935-41.
19. Jakubowski H, Zhang L, Bardeguez A, Aviv A: Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res 2000;l87:45-51.
20. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13:2277-83.
21. Jakubowski H. Homocysteine is a protein amino acid in humans: Implications for homocysteine-linked disease. J Biol Chem 2002; 277:30425-8.
22. Glowacki R, Jakubowski H. Cross-talk between Cys-34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem 2004;279:10864-71.
23. Ferretti G, Bacchetti T, Marotti E, Curatola GT. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 2003;52:146-51.
24. Ferretti G, Bacchetti T, Moroni C, Vignini A, Nanetti L, Curatola GT. Effects of homocysteinylation on low density lipoprotein peroxidation of human endothelial cells. J Cell Biochem 2004;92:351-60.
25. Ferguson E, Parthasarathy S, Joseph J, Kalyanaraman B. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low-density lipoprotein. J Lipid Res 1998;39:925-33.
26. Undas A, Perla J, Łaciński M, Trzeciak W, Kaźmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004;35:1299-304.
27. Daneshvar P, Yazdanpanah M, Cuthbert C, Cole DE. Quantitative assay of plasma homocysteine thiolactone by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2003;17:258-62.
28. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J Biol Chem 2000;275:3957-62.
29. Jakubowski H, Ambrosius W, Pratt JH. Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis. FEBS Lett 2001;491:35-9.
30. Anderson RF, Packer JE. The radiolysis of aqueous solutions of homocysteine thiolactone. Int J Radiat Phys Chem 1974;6:33-46.
31. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000;20:1704-6.
32. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
33. Mukai Y, Togawa T, Suzuki T, Ohata K, Tanabe S. Determination of homocysteine thiolactone and homocysteine in cell cultures using high-performance liquid chromatography with fluorescence detection. J Chromatogr B 2002;767:263-8.
34. Dudman NP, Hicks C, Lynch JF, Wilcken DE, Wang J. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb 1991;11:663-70.
35. Van Guldener C, Stehouver CD. Homocysteine metabolism in renal disease. Clin Chem Lab Med 2003;41:1412-7.
36. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997;52:495-502.
37. Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Budy B, et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001;276:30111-7.
38. Brater DC, Kaojarern S, Benet LZ, Lin ET, Lockwood T, Morris RC, et al. Renal excretion of pseudoephedrine. Clin Pharmacol Ther 1980;28:690-4.
39. Heinegard D, Tiderstrom G. Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta 1973;43:305-10.